Monte Rosa Therapeutics, Inc. GLUE Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s total operating expenses?
- Monte Rosa Therapeutics, Inc. (GLUE) reported total operating expenses of $54.24M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s total operating expenses increased by 32.6% year-over-year, from $40.89M to $54.24M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s total operating expenses has grown at a 25.0% compound annual growth rate (CAGR), from $72.88M to $177.88M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.